New cancer combo trial seeks to boost immune attack on tumors
NCT ID NCT03907475
Summary
This study is testing whether adding an immunotherapy drug called durvalumab to standard chemotherapy is safe and effective for patients with advanced solid tumors that have spread. The goal is to see if the combination helps the patient's own immune system better recognize and attack cancer cells. About 115 adults whose cancer has progressed after at least one prior treatment will receive one of several different chemotherapy drugs paired with durvalumab.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Institute Developmental Therapeutics Clinic
RECRUITINGBethesda, Maryland, 20892, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.